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The safety and efficacy of a new clinical synchronized 
diastolic retroperfusion mechanical pump and auto in-
f1atable balloon catheter was studied in 10 dogs during 
and after 6 hours of left anterior descending coronary 
artery occlusion. Eight other dogs served as the un-
treated control group. Infarct size measured by tri-
phenyltetrazolium chloride, and expressed as a percent 
of area at risk, was significantly reduced by retroper-
fusion treatment (19 ± 18 versus 58 ± 36, P < 0.01). 
Morphologic examination of the coronary sinus and car-
There has been considerable interest in the use of the coro-
nary venous system to nourish the myocardium since Rob-
erts et al. (1) and Beck et al. (2) demonstrated that coronary 
sinus retroperfusion offered protection against acute coro-
nary occlusion in experimental animals. The first clinical 
application was the Beck II procedure, a two stage operation 
in which a shunt was created between the aorta and the 
coronary sinus, followed by partial coronary sinus outflow 
obstruction to enhance retrograde flow. Introduced before 
modem surgical and cardioplegic techniques, the operative 
mortality was high. However, many of the survivors had 
an excellent early surgical result with marked symptomatic 
improvement, only to later develop congestive heart failure 
(3,4). Postmortem examination revealed that many of the 
patients had severe myocardial edema, most likely caused 
by interference with normal coronary venous drainage. This 
finding has been confirmed in subsequent experimental stud-
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diac veins did not demonstrate evidence of damage from 
synchronized retroperfusion. There was also no evidence 
of excess myocardial edema in either the jeopardized 
ischemic or normally perfused zones. There was no evi-
dence of significant red cell hemolysis or platelet de-
struction from the treatment. Thus, it appears that syn-
chronized diastolic retroperfusion is a safe and effective 
treatment of acute myocardial ischemia in experimental 
animals and warrants clinical testing. 
(J Am Call CardioI1985;6:328-35) 
ies using both coronary sinus retroperfusion and selective 
coronary venous retroperfusion (3,5,6). Severe myocardial 
hemorrhage from excessive retrograde coronary venous flow 
has also been identified as a potential complication of this 
procedure (2,7-9). 
In 1976, Meerbaum et al. (10) developed a procedure 
known as synchronized coronary venous retroperfusion. This 
technique differs from the Beck procedure and other surgical 
coronary venous retroperfusion techniques in several ways. 
First, synchronization provides retroperfusion during dias-
tole, while permitting normal physiologic coronary venous 
drainage during systole. Second, the method is intended as 
a temporary treatment for acute myocardial ischemia pend-
ing some other definitive treatment, such as coronary artery 
thrombolysis, coronary artery bypass graft surgery or per-
cutaneous transluminal coronary angioplasty. Since its in-
troduction, several studies have been published (11-14) which 
confirm the beneficial effects of synchronized retroperfusion 
in experimental animals. 
We have recently developed a prototype piston-driven 
synchronized retroperfusion system and a soft-tipped au-
toinflatable balloon catheter for clinical use. The purpose 
of this study was to test the safety and efficacy of this new 
system in animals before initial use in human beings. 
Methods 
Experimental preparation. Twenty-three healthy mon-
grel dogs weighing 25 to 40 kg were anesthetized with 
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intravenous sodium pentobarbital (30 mg/kg body weight) 
20 minutes after premedication with intramuscular morphine 
(2 mg/kg). Supplemental doses of sodium pentobarbital (3 
mg/kg) were given as necessary to maintain a continuous 
state of light anesthesia. After endotracheal intubation, ar-
tificial respiration was controlled by a Harvard respirator 
pump. Heparin (10,000 IU) was given intravenously before 
instrumentation and supplemented when necessary at hourly 
intervals to maintain activated clotting times of greater than 
480 seconds. A 2F balloon catheter was introduced per-
cutaneously and placed under fluoroscopic control in the 
left anterior descending coronary artery. 
Aortic and left ventricular pressures were monitored with 
fluid-filled catheters connected to Statham P23Db trans-
ducers. A 7F thermodilution pulmonary artery flotation cath-
eter (American Edwards Laboratories) was placed in the 
pulmonary artery for measurement of cardiac output. The 
electrocardiogram and all pressures were monitored contin-
uously with an Electronics for Medicine V -12 physiologic 
recorder. 
Synchronized retroperfusion (Fig. 1). A schematic of 
the prototype electrocardiographically synchronized retro-
perfusion system is shown in Figure I. Arterial blood is 
shunted from a brachial artery through an 8F catheter to a 
disposable pump chamber. Blood is then delivered to the 
great cardiac vein through a 7F soft-tipped autoinflatable 
balloon catheter during diastole. During systole, balloon 
deflation permits normal coronary venous outflow. 
The retroperfusion system consists or I) a Hewlett-
Packard 78346A monitor for display of the cardiac rhythm, 
arterial pressure and the pump signal; 2) controls that permit 
electrocardiographic synchronization of blood delivery and 
Figure 1. Schematic of the synchronized retroperfusion (SRP) 
system. Arterial blood is shunted from a brachial artery to the 
pump chamber. During diastole the upward movement of a piston 
onto the pump chamber displaces blood through an auto inflatable 
balloon catheter into the coronary sinus. AI = anterior interven-
tricular; EM = electromagnetic; LAD ART. = left anterior de-
scending coronary artery. 
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regulation of the amount of retroperfusion flow; 3) a me-
chanical pump that propels blood into the coronary vein by 
mechanical displacement provided by the upward movement 
of a piston onto the pump chamber; and 4) a disposable 
pump-reservoir chamber and connecting tubing. Two dif-
ferent pump-reservoir chambers were used, because the 
original model (Fig. 2A) was found to cause hemolysis 
during the initial retroperfusion studies and, thus, was mod-
ified to permit a less tortuous pathway for blood flow (Fig. 
2B). 
Experimental protocol. In all dogs, the left anterior 
descending coronary artery was occluded proximal to the 
first diagonal branch by inflation of a 2F balloon catheter. 
Immediately before occlusion, lidocaine (100 mg) was ad-
ministered intravenously, followed by a continuous intra-
venous infusion of 2 mg/min for 30 minutes. Supplemental 
doses of lidocaine (50 mg) were given as necessary for 
complex ventricular arrhythmia. Twenty dogs survived the 
first 30 minutes of coronary occlusion and were eligible for 
randomization to the control or treated group. Three dogs 
died of ventricular fibrillation. One dog did not demonstrate 
electrocardiographic or echocardiographic evidence of myo-
cardial ischemia and was excluded, leaving 19 dogs for 
randomization. The control group (9 dogs) received no treat-
ment, whereas the treated group (10 dogs) received syn-
chronized retroperfusion of arterial blood by way of the 
great cardiac vein from 30 minutes after occlusion until 
sacrifice at 6 hours. The original pump chamber (Fig. 2A) 
was used in six of the animals in the treated group and the 
modified chamber (Fig. 2B) in four animals. The retroper-
fusion flow was gradually increased from 30 to 60 ml/min 
over 5 minutes and then maintained at 50 to 60 mllmin for 
Figure 2. Original (A) and modified (B) pump chamber assem-
blies. Arterial blood first enters a reservoir chamber (black arrows) 
and then, during systole, a pump chamber (white arrows). Upward 
movement of a piston onto the pump chamber displaces blood into 
the coronary sinus. A one-way valve between the reservoir and 
pump chambers prevents backward flow. The only difference be-
tween the two models is that the pathway from the reservoir into 
the pump chamber is more tortuous in model A than in model B. 
DB 
330 DRURY ET AL. 
DIASTOLIC RETROPERFUSION: SAFETY AND EFFICACY 
the remainder of the experiment. Sequential hemodynamic 
measurements in both treatment groups were obtained be-
fore occlusion and at 30,60 and 360 minutes after occlusion. 
Retroperfusion flow was measured with a Micron (RC 1000) 
electromagnetic flowmeter by placing a 4 mm flow probe 
immediately proximal to the coronary sinus catheter. 
Hematologic measurements. Blood samples for red cell, 
white cell an~ platelet counts and plasma free hemoglobin 
levels were obtained from a femoral vein before coronary 
occlusion and before sacrifice after 6 hours of maintained 
coronary art~ry occlusion. 
Postmortem study. The area at risk was determined by 
injection of O.S mllkg monastral blue dye into the left ven-
tricle immediately before sacrifice. The hearts were cut into 
I cm thick slabs and photographed. The non stained myo-
cardium represented the underperfused area at risk. The 
extent of necrosis was determined by planimetry after in-
cubation of the myocardial slabs in triphenyItetrazolium 
chloride 'ls described previously (IS). Gross and micro-
scopic inspections of the coronary sinus and coronary veins 
were performed in all dogs to detect any possible damage 
that might be caused by r~troperfusion. Myocardial edema 
was assessed by incubating biopsy samples obtained from 
jeopardized (myocardium not stained by monastral blue) and 
nonjeopardizeq (myocardium stained by monastral blue) re-
gions at 100°C for 24 hours. The differences between the 
dry and wet weights of the biopsy samples were expressed 
as percent myocardial water content. In addition, the post-
mortem cardiac weight was determined for both the treated 
and control animals and expressed as a percent of the dog's 
body weight. 
Statistical analysis. The effects of coronary artery oc-
clusion and retroperfusion on hemodynamics, infarct size, 
hematologic indexes and myocardial water content were 
compared using Student's t test for unpaired data. Unless 
otherwise indicated, data are expressed as mean values ± 
standard deviation. 
Results 
Diastolic coronary venous retroperfusion. This pro-
cedure was accomplished in all 10 of the treated animals 
without difficulty. The maximal time for insertion of the 
retroperfusion catheter into the great cardiac vein was IS 
minutes and the usu~l insertion time was less than 7 minutes. 
The arterial source catheter was inserted into the brachial 
artery within 2 to 3 minutes. After placement of both the 
brachial artery am! coronary sinus catheters, the retroper-
fusioll system was made operative within I to 2 minutes by 
connecting the pump chamber inlet tubing to the arterial 
catheter, purging air out of the tubing with the animal's 
own blood and then connecting the outlet tubing to the 
coronary sinus catheter. Diastolic retroperfusion was ac-
complished by sypchronizing the pump stroke to the R wave 
lACC Vol. 6. No, 2 
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Figure 3. Coronary sinus flow tracing demonstrating the electro-
cardiogram (ECP), the R wave-triggered pump stroke display (SRP 
pulse), the left ventricular (LVP) and pulmonary artery (PA) pres-
sure tracings and the phasic coronary sinus electromagnetic flow 
tracing (EMQ). The coronary sinus flow is retrograde during di-
astole (peak flow 300 mllmin) and anterograde during systole. 
of the electrocardiogram (Fig. 3). It was possible to deliver 
the entire retroperfusion flow in diastole in all dogs by using 
a delay time from the R wave equivalent to 4S% of the RR 
cycle and a retroperfusion stroke time of SO% of the RR 
cycle. The retroperfusion flow used in this experiment was 
SS ± S mllmin and the electromagnetic flowmeter showed 
the precalibrated system to the accurate within ± 10%. 
Hemodyna,nics (Table 1). There were no significant 
hemodynamic differences between the control and treated 
groups in the preocclusion state and at 30 minutes postoc-
clusion. The only statistically significant difference between 
the two groups after treatment was a lower pulmonqry wedge 
pressure in the treated group at 6 hours after coronary oc-
clusion. The cardiac index, stroke volu!l1e index and stroke 
work index appeared higher in the treated group compared 
with the control group at 6 hours of occlusion (SI/2 hours 
treatment); however, these differences did not reach statis-
tical significance. There were no serious ventricular ar-
rhythmias in either group after randomization, except for 
one control dog that died of ventricular fibrillation after 90 
minutes of occlusion and was excluded from further anal-
ysis. In particular, there was no eviqence of an increase in 
ventricular ectopic activity in the treated group with initi-
ation of retroperfusion. 
Hematologic data (Table 2). Hematocrit, white cell count 
and platelet count were similar in the control and treated 
groups despite SI/2 hours of retroperfusion. There was some 
hemolysis in both groups as evidenced by an increase in the 
plasma free hemoglobin levels after 6 hours of coronary 
occlusion. The free hemoglobin level in the retroperfusion 
group using the original pump cha!l1ber assembly (Fig. 2A) 
was significantly higher compared with the level in the con-
trol group after Slj2 hours of retroperfusion, suggesting that 
lACC Vol. 6. No.2 
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Table 1. Hemodynamic Data in Dogs With Untreated Coronary Occlusion and With 
Diastolic Retroperfusion 
Heart rate (beats/min) 
CTR 
SRP 
AP (mm Hg) 
CTR 
SRP 
PWP (mm Hg) 
CTR 
SRP 
SVR (dynes·s-cm ) x 10' ) 
CTR 
SRP 
CI (liters/min per m2) 
CTR 
SRP 
SVI (mllbeat per m2) 
CTR 
SRP 
SWI (g/beat per m2) 
CTR 
SRP 
Preocclw,ion 
102 ± 27 
101 ± 37 
113 ± 22 
108 ± 10 
2.1 ± 1.4 
1.3 ± 0.5 
4.1 ± 1.3 
3.9 ± 1.0 
2.1 ± 0.4 
2.1 ± 0.5 
22 ± 8 
21 ± 8 
17 ± 16 
34 ± 9 
Time After Coronary Occlusion 
30 min 60 min 6 h 
139 ± IJ 143 ± 21 155 ± 4X 
119 ± 29 123 ± 23 126 ± 20 
108 ± 30 116 ± 24 95 ± 25 
101 ± 19 101 ± 15 102 ± 24 
4.3 ± 4.1 3.4 ± 2.X 2.9 ± 1.6 
1.9 ± 1.2 2.1 ± 1.3 1.3± 1.1* 
3.4 ± 1.5 4.7 ± 2.6 4.9 ± 2.2 
3.8 ± 1.5 3.7 ± 2.1 5.3 ± 2.9 
2.6 ± 0.7 2.2 ± (UI 1.4 ± 0.3 
2.1 ± 0.8 2.1 ± 0.7 1.6 ± 0.8 
19 ± 5 16 ± 8 10 ± 4 
18 ± 8 17 ± 16 12 ± 6 
28 ± 12 25 ± II 13 ± 8 
28 ± 14 26 ± 14 18 ± 12 
*p < 0.05 relative to control group. Values are mean ± SO. AP = mean aortic pressure; CI = cardiac 
index; CTR = control; PWP = mean pulmonary wedge pressure; SRP = diastolic retroperfusion; SVI 
stroke volume index; SVR = systemic vascular resistance; SWI = stroke work index. 
additional hemolysis occurred secondary to the treatment. 
However, the level of hemolysis in the retroperfusion group 
in which the modified pump chamber assembly was used 
(Fig. 2B) was similar to that of the control group. 
Pathologic findings (Table 3, Fig. 4). The area at risk 
was similar in the untreated and retroperfusion-treated groups, 
being 15.4 ± 2.7 and 14.7 ± 4.5% of the left ventricle, 
respectively. Infarct size expressed both as a percent of the 
left ventricle (3.2 ± 3.9 versus 8.5 ± 5.5, p < 0.05) and 
as a percent of the area at risk (18.6 ± 18.2 versus 57.8 
± 35.8, P < 0.01) was significantly lower in the retroper-
fusion-treated group. Eight of the 10 treated dogs had an 
Table 2. Hematologic Results 
Time 
(postoccIusion) 
Pre-O 
6h 
HCT 
CTR SRP 
41 ± 7 40 ± 2 
37 ± 8 40 ± 7 
WBC 
(X 10'/mm') 
CTR SRP 
7 ± 5 8 ± 6 
16 ± 3 10 ± :; 
infarct area less than 5% of the left ventricle compared with 
only 2 of the 3 untreated dogs. Moreover, only one of the 
treated dogs, but five of eight untreated dogs, had an infarct 
area greater than 50% of the risk zone. In general, the 
infarcts in the treated dogs were in the subendocardial region 
of the apical slices; however, two dogs (S2 and S9) did 
have a transmural infarct. There was no evidence of myo-
cardial hemorrhage in the infarct or peri-infarct region of 
the dogs treated with retroperfusion. 
The intima of the coronary sinus, great cardiac vein and 
anterior interventricular veins was intact in all dogs, in-
cluding those treated with diastolic retroperfusion for 5 111 
Plateleh 
(X 10'/mm') 
CTR SRP 
224 ± 76 173 ± 65 
210 ± 106 196 ± 49 
CTR 
17 ± 17 
Free Hb 
(mg/dl) 
SRP-I 
36 ± 27 
* * 
SRP-II 
33 ± 17 
/"'- /"---
98 ± 36 221 ± 114 62 ± 64 
\~--------=-------_/ 
NS 
*p < 0.05. Values are mean ± SD. Free Hb = plasma free hemoglobin; HCT = hematocrit; NS = not significant; Pre-O = preocclusion; 
SRP-I = original retroperfusion pump chamber; SRP-II = modified retroperfusion pump chamber; WBC = white cell count; other abbreviations as in 
Table I. 
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Table 3. Infarct Size in Dogs With Untreated Coronary 
Occlusion (Cl and With Diastolic Retroperfusion Treatment (S) 
Risk Area Necrotic Area Necrotic Area 
Dog (% LV) (% LV) (% risk area) 
CI 14 13 92 
C2 14 8 57 
C3 15 13 87 
C4 17 I 6 
C5 20 2 10 
C6 18 16 89 
C7 12 10 83 
C8 13 5 38 
Mean 15.4 8.5 57.8 
± SD 2.7 5.5 35.8 
SI 18 4 22 
S2 23 12 52 
S3 14 I 7 
S4 12 8 
S5 19 I 5 
S6 II 3 27 
S7 14 7 
S8 9 I II 
S9 17 8 47 
SIO 10 0 0 
Mean 14.7 3.2* 18.6t 
± SD 4.5 3.9 18.2 
*p < 0.05 relative to Group C; tp < 0.01 relative to Group C. LV 
= left ventricle. 
hours. In particular, there was no evidence of injury to the 
veins either from the catheter tip or from repeated inflation 
and deflation of the balloon in the great cardiac vein. In 3 
of the 10 treated dogs, there was evidence of bruising at 
the coronary sinus orifice (Fig. 4a), most likely caused by 
manipulation of the catheter tip in the right atrium during 
attempts to enter the coronary sinus. In one-half of the dogs 
of both series there was hemorrhage in the epicardial fat 
surrounding the left anterior descending coronary artery and 
the anterior interventricular vein (Fig. 4b). This occurred 
as frequently in the control animals (4 of 8) as in the treated 
animals (5 of 10). The hemorrhage was classified as minor 
(that is, restricted to subepicardium and involving less than 
5% of the surface of the left ventricle) in all but one case. 
This exception was a dog in the control group (C6) that had 
an extensive hemorrhage extending into the midmyocardiu!l1 
and involving approximately 50% of the left ventricle. This 
dog had the Ilj.rgest infarct of all the animals, involving 16% 
of the left ventricle and 89% of the risk area. In one treated 
dog a nonocclusive microscopic thrombus was found ad-
hering to the wall of the great cardiac vein (Fig. 4c). 
Myocardial edema (Table 4). There was no difference 
in water cO!1tent between the untreated and retroperfusion-
treated groups in both the jeopardized ischemic (monastral 
blue negative) and the nonischemic (monastral blue positive) 
zones. The endocardial and epicardial water content was 
lACC Vol. 6. No.2 
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also similar in both groups. Moreover, heart weight, nor-
malized for total body weight, was similar in the two groups. 
Discussion 
Coronary venous retroperfusion has been suggested as 
an alternate treatment of acute myocardial ischemia. Several 
investigators have demonstrated the efficacy of retroperfu-
sion by both permanent arterial anastomosis and temporary 
synchronized diastolic retrograde blood delivery. However, 
there has been concern about the safety of the technique. 
Factors identified as potentially dangerous include: 1) major 
interference with coronary sinus drainage (16); 2) excessive 
retrograde flow rates (17-19); and 3) direct trauma to the 
coronary sinus from catheterization with a rigid catheter 
(20). This study was performed to confirm the efficacy of 
a newly manufactured prototype retroperfusion system and 
to test its safety in animals before clinical use. 
Synchronized retroperfusion effe~tiveness. This study 
demonstrates that synchronized diastolic retroperfusion ef-
fectively limits myocardial necrosis for a period of 6 hours 
after acute coronary occlusion in experimental animals. This 
result is in agreement with other investigations which have 
shown myocardial salvage with retroperfusion for shorter 
periods of coronary occlusion. Although not reported in this 
paper, retroperfusion has also been shown to significantly 
improve global and regional left ventricular function 
(10,11,13,21). 
Synchronized retroperfusion safety. We have also 
demonstrated that synchronized diastolic retroperfusion for 
periods of 5th hours may be performed safely in the ex-
perimental animal. There was no evidence of significant 
damage to blood cells at flow rates of 60 mllmin. Plasma 
free hemoglobin level, a sensitive indicator of red cell hem-
olysis, was elevated compared with that ill the control group 
with the original pump chamber, but not with that in the 
group with the modified chamber which permitted a less 
tortuous pathway for blood flow. 
There were no serious arrhythmia& wjth retroperfusion 
when the retrograde flow was gradually increased during 
the first 5 minutes of treatment. This finding is in contrast 
to the increase in ventricular irritability whjch has been noted 
with sudden anterograde reperfusion (22,23) and also with 
retroperfusion initiated at high flow rates (13). The absence 
of arrhythmias with retroperfusion is probably related to the 
gradual delivery of arterial blood to the ischemic myocar-
dium with the retrograde treatment. 
Careful gross and microscopic morphologic examination 
of the coronary sinus and coronary veins did not reveal any 
evidence of significant damage from diastolic retroperfu-
sion. In particular, there was no evidence of damage to the 
intima of the coronary sinus or great cardiac vein from the 
catheter itself, and 110 evidence of damage to the great car-
Figure 4. Pathologic sections. a, Photograph of the right atrium 
in a treated dog demonstrating bruising of the atrial wall (arrow) 
near the orifice of the coronary sinus (cs). b, Photomicrograph of 
the left anterior descending coronary artery (a) and anterior inter-
ventricular vein (v) in a treated dog demonstrating hemorrhage (H) 
in the epicardial fat surrounding the vessels (hematoxylin-eosin 
stain, original magnification x 16, reduced by 38%). C, Photo-
micrograph of the great cardiac vein in a treated dog demonstrating 
a nonocclusive thrombus (T) and perivascular hemorrhage (H) 
(hematoxylin-eosin stain, original magnification x 16, reduced 
by 38%). d,e, Myocardial slabs stained with triphenyltetrazolium 
chloride from a treated (d) and a control (e) dog demonstrating 
the extent of myocardial necrosis (unstained segments). 
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Table 4. Cardiac Weight and Myocardial Water Content in Control and Treated Groups 
Myocardial Water Content (o/c) 
Cardiac Wt 
Ischemic Nonischemic 
Group (mg/kg) Endo Epi Endo Epi 
CTR 7.10 ± 0.16 81.6 ± 1.7 80.7 ± 2.1 81.3 ± 2.7 80.0 ± 2.4 
SRP 7.17 ± 0.18 SI.7 ± 1.2 SI.2 ± 1.7 SO. I ± 1.5 79.3 ± O.S 
Values are expressed as mean ± SD. Endo 
abbreviations as in Table I. 
endocardial; Epi epicardial; Wt weight; other 
diac vein from balloon inflation. There was minor bruising 
of the orifice of the coronary sinus, but this was not asso-
ciated with significant hemorrhage. In one dog there was a 
microscopic thrombus in the great cardiac vein despite an-
ticoagulation, but this thrombus was nonocclusive. The ab-
sence of significant coronary venous damage was probably 
related to the use of a soft-tipped catheter in this study. 
There was evidence of superficial epicardial hemorrhage 
in 50% of the animals; however, the hemorrhage was present 
as frequently in the control group as in the experimental 
group. Moreover, the hemorrhage was confined to the sub-
epicardium in all but one case, extending neither into the 
pericardial cavity nor into the myocardium itself. The one 
exception was a control dog with a large myocardial infarct 
in which the hemorrhage extended into the midmyocardium. 
Because the hemorrhage occurred as frequently in the con-
trol dogs, which had neither a coronary sinus catheter nor 
retroperfusion, it is unlikely that diastolic retroperfusion was 
responsible. The most likely cause of the bleeding was rup-
ture of small epicardial vessels from overinflation of the 
balloon catheter used in our experimental model to occlude 
the left anterior descending coronary artery. The tendency 
for hemorrhage was probably augmented by heparinization 
of the animals. 
Myocardial edema. which has been identified as a po-
tential complication of coronary sinus retroperfusion, did 
not occur in this study. Its absence was most likely sec-
ondary to preservation of adequate physiologic coronary 
venous drainage with systolic balloon deflation and avoid-
ance of excess retrograde flows. Although coronary venous 
pressure was not measured, previous experimental work has 
shown a relation between coronary venous retrograde flow, 
coronary venous pressure and myocardial edema and hem-
orrhage. Several investigators (24,25) found that prolonged 
coronary venous hypertension, that is, mean pressure greater 
than 40 mm Hg or peak pressure greater than 60 mm Hg, 
or both, causes significant damage. Previous work in our 
laboratory using an open chest dog model and direct mea-
surement of coronary venous pressure has shown that with 
mean diastolic retroperfusion flows of 50 to 60 mllmin, 
mean coronary venous pressure is reliably maintained at less 
than 30 mm Hg, with peak pressures less than 50 mm Hg. 
Clinical implications. This experimental study suggests 
that synchronized diastolic coronary venous retroperfusion 
may be applied promptly and without significant risk. This 
and other studies have also demonstrated that retroperfusion 
improves left ventricular function and limits myocardial ne-
crosis when applied during experimental myocardial isch-
emia. If also effective in human patients, diastolic retro-
perfusion might significantly reduce the morbidity associated 
with acute myocardial infarction. Moreover, retroperfusion 
might also provide myocardial protection during procedures 
such as percutaneous transluminal coronary angioplasty, which 
involves the temporary interruption of anterograde coronary 
blood flow and is complicated by myocardial necrosis in a 
small but significant percent of patients (26). 
We recognize the need for caution whenever results of 
animal research are extrapolated to clinical practice. Al-
though the dog is a useful experimental model, its coronary 
artery and vein anatomy differs from the native vasculature 
in human hearts, which is further modified by atheroscle-
rosis. Experimental conditions and measurements are much 
easier to control in the animal laboratory than in clinical 
practice, and the duration of ischemia before the treatment 
of human patients is generally much longer than the 30 
minutes of reversible ischemia preceding intervention in our 
study. Further experimental animal research will be nec-
essary to clarify the effectiveness of retroperfusion initiated 
after longer periods of ischemia and maintained for longer 
durations of treatment. Supplementary use of an animal 
model such as the pig, which has minimal coronary collat-
eral flow, is also desirable to determine the potential effec-
tiveness of retroperfusion in patients without a well devel-
oped collateral circulation. 
Nonetheless, the effectiveness of synchronized diastolic 
retroperfusion has been demonstrated through a substantial 
number of studies during the last decade employing different 
animal species and a variety of experimental conditions. We 
believe that the results of these studies are sufficiently prom-
ising to justify introduction of this experimental technique 
into clinical practice, recognizing that well controlled clin-
ical trials will be essential to properly evaluate the role of 
synchronized retroperfusion in the treatment of acute myo-
cardial ischemia. 
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